This site is intended for UK Healthcare Professionals only.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App Store. Adverse events should also be reported to Cipla (EU) Ltd on 0800 0472144, drugsafety@cipla.com
About Cipla
Cipla is the 2nd-largest global manufacturer of respiratory inhalers.4 Cipla (EU) Limited is a wholly-owned subsidiary of Cipla Limited, a global pharmaceutical company, which ranks first in India and fourth in North America in terms of number of respiratory prescriptions.4
We are highly experienced in respiratory care, with over 40 years’ history in developing, producing and supplying products.4
Cipla provides reliable manufacture and supply of our products. Cipla products are available through all major wholesalers. We have 46 state-of-the-art manufacturing facilities worldwide and are dedicated to ensuring a consistent and reliable supply chain.4
Cipla is dedicated to improving sustainability across our respiratory range in support of the NHS goal of becoming carbon net zero by 2040.3,12
From the 1st June 2023, Cipla has implemented a carbon-offsetting scheme for the propellant used in our entire pMDI range in the UK.3,13
We have committed to the following in production sites in India, where our respiratory range is manufactured.*
By 2025 we aim to achieve.4
- carbon neutrality (for our Scope 1 (fuelbased) and Scope 2 emissions)
- water neutrality
- zero waste to landfill
We are committed to developing sustainable alternatives to certain propellants in the near future.4
*India Manufacturing Operations include manufacturing sites of Cipla Limited and our subsidiaries in India
Discover more about Cipla by clicking on the links below:
pMDI = pressurised metered dose inhaler.